ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Serum melatonin predicts hepatic encephalopathy in patients with liver cirrhosis.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimHepatic encephalopathy (HE) is a serious complication in patients with liver cirrhosis and is strongly associated with morbidity and mortality. Melatonin, a neuroprotective hormone secreted by the pineal gland and enterochromaffin cells of the gastrointestinal tract is involved in the sleep cycle in normal people. This may be disrupted in cirrhotic patients. We aimed at evaluating the role of serum melatonin in cirrhotic patients with HE.
methodsA prospective observational study was conducted in hospitalized patients with liver cirrhosis after meeting the inclusion and exclusion criteria. Morning melatonin levels were measured in patients categorized into three groups based on their progression of HE according to West Haven criteria (WHC) as group 1 (no HE), group 2 (WHC grades I and II) and group 3 (WHC grades III and IV). Biochemical measurements were done using standardized procedures.
resultsFifty-two patients underwent morning melatonin levels, with a mean age of 55.46 ± 12.26 years old, and nine (17.3%) patients were women. The morning melatonin levels (pg/mL) of healthy volunteers and liver cirrhosis patients were 23.88 (range, 12.54-31.32) and 190 (range, 30.53-300) pg/mL. Among cirrhotic patients, group 1 (n = 11), group 2 (n = 27) and group 3 (n = 14), the morning melatonin levels were (pg/mL) 45.62 ± 15.09, 214.01 ± 107.78 and 280.98 ± 52.74 (p < 0.001), respectively. The correlation coefficient (r) between morning melatonin levels and the grades of HE was 0.797 (p < 0.001). A serum melatonin level of ≥ 85 pg/mL predicted HE with a sensitivity of 86.96%, specificity of 100%, positive predictive value of 100%, negative predictive value of 71.43% and accuracy of 90.16%. The area under the receiver operating characteristic curve (AUROC) for melatonin in predicting HE was 0.94 (p < 0.001).
conclusionSerum melatonin levels are significantly higher in HE patients with liver cirrhosis, with the highest levels measured in patients with the most severe grade of HE. A melatonin level of ≥ 85 pg/mL was associated with HE and level ≥ 248.95 pg/mL was associated with severe HE. Prospective large studies are required to validate the role of melatonin as a prognostic marker.
Indexed as
Identifiers
41559350What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.